Thrombosis and anticoagulation in patients with Cirrhosis. An overview

Area of Science:

• Hepatology
• Cardiology
• Hematology

Background:

• Cirrhosis patients are not spontaneously anticoagulated.
• Cirrhosis patients have increased risk for venous thromboembolism (VTE) and atrial fibrillation.
• Portal vein thrombosis (PVT) is a marker of liver disease severity.

Purpose of the Study:

• To evaluate the role and safety of anticoagulation in patients with cirrhosis.
• To assess the impact of anticoagulation on bleeding risk and mortality in cirrhosis.
• To determine the efficacy of anticoagulation in patients with and without PVT.

Main Methods:

• Review of current literature and clinical data on anticoagulation in cirrhosis.
• Analysis of VTE prophylaxis and treatment strategies in hospitalized cirrhosis patients.
• Evaluation of direct oral anticoagulants (DOACs) in non-decompensated cirrhosis.

Main Results:

• Anticoagulation does not independently increase bleeding risk or mortality in cirrhosis.
• VTE prophylaxis is recommended for hospitalized cirrhosis patients.
• Deep vein thrombosis and pulmonary embolism require anticoagulation treatment.
• PVT is a severity marker, not an aggravating factor for bleeding.
• Anticoagulation therapy is beneficial for cirrhosis patients with or without PVT.
• DOACs are preferred for anticoagulation in non-decompensated cirrhosis.

Conclusions:

• Anticoagulation is safe and beneficial for managing VTE and atrial fibrillation in cirrhosis patients.
• Consider VTE prophylaxis and treatment with anticoagulation in hospitalized cirrhosis patients.
• DOACs are a primary choice for anticoagulation in stable cirrhosis patients.